On July 25, 2020, the Turkish Medicine and Medical Devices Authority ("TITCK") updated its Frequently Asked Questions (FAQ) document and COVID-19 measures document regarding clinical trials. The TITCK's relevant announcements and updated documents are available online here (in Turkish).
The TITCK updated the application procedures for clinical trial meetings held online during the pandemic:
- The 30-day period for meeting applications filed with the TITCK will now be five business days. In other words, applicants must file their meeting applications to the TITCK within five business days before the meeting date.
- The applicants will be able to file meeting applications with the TITCK for clinical trials that are not officially approved by the Ethics Committee or the TITCK. However, for these applications, the applicants must submit a copy of the cover letter relating to the initial application to the Ethics Committee.
In addition, the TITCK noted that it will apply expedited assessment procedures for clinical trial applications relating to COVID-19.
As per the updates to the FAQ documents, the TITCK provided additional explanations for on-premise monitoring activities, applications through the clinical trial module and COVID-19 PCR tests performed during the clinical trials.
The TITCK continues to take active steps to protect the public against the COVID-19 pandemic in Turkey. All sponsor companies must implement the TITCK's measures, integrate them to their processes and conduct risk assessments.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.